Phase I study of paclitaxel with oral etoposide in advanced solid tumors

Cancer Journal from Scientific American

Volumn 2, Issue 5, 1996, Pages 286-290

  Perez, Edith A ^a   Coe, Tracy ^b   Turrell, Corinne ^b   Lau, Derick ^b   Campbell, David ^b   Gandara, David ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

Etoposide; Paclitaxel; Phase I study; Solid tumors

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; PACLITAXEL;

AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL; SURVIVAL RATE;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; SURVIVAL RATE;

EID: 0009703696     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Nad Cancer Inst 1990; 82:1247-1259.
2. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981;91:479-487.
3. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 1987;71:1171-1177.
4. Brown T, Havlin K, Weiss G et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991;9:1261-1267.
5. Long BH, Musial ST, Brattain MG. Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship. Biochemistry 1984;23:1183-1188.
6. Long BH. Structure-activity relationships of podophyllin congeners that inhibit topoisomerase II. NCI Monogr 1987;4:123-127.
7. Dombernowsky P, Nissen NJ. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. Acta Pathol Microbiol Scand 1973;81:715-724.
8. Hainsworth JD, Johnson DH, Frazier SR, Greco FA. Chronic daily administration of oral etoposide - a phase I trial. J Clin Oncol 1989;7:396-401.
9. Splinter TAW, van der Gaast A, Kok TC. What is the optimal dose and duration of treatment with etoposide? I. Maximum tolerated duration of daily treatment with 50, 75, and 100 mg of oral etoposide. Semin Oncol 1992;19 [suppl 14]:1-7.
10. Clark P, Cottier B, Joel S, Slevin M. Two prolonged schedules of single-agent oral etoposide of differing duration and dose in patients with untreated small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol 1991;10:268.
11. Hahn SM, Liebmann JE, Cook J et al. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro. Cancer 1993;72:2705-2711.
12. Rose WC. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. NCI Monogr 1993;14:47-53.
13. Perez EA, Hack F, Fletcher T, Martinez VA. Sequence dependent cytotoxicity of taxol (Tax) and etoposide (Eto) in lung and breast human cancer cell lines [abstract]. Proc Am Soc Clin Oncol 1995; 14:491.
14. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-2666.
15. Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-190.
16. Minami H, Ando Y, Sakai S, Shimokata K. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J Clin Oncol 1995;13:191-199.
17. Clark PI, Slevin ML, Joel SP et al. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 1994; 12:1427-1435.